Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC, Han JY, Kim SW, Lee KH, Cho EK, Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, Shim BY, Kim JS, Chun SH, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Lee Y, Lee DH, Kang JA, Lee N, Kwon MJ, Espenschied C, Yablonovitch A, Ahn MJ. Cho BC, et al. Among authors: yablonovitch a. J Thorac Oncol. 2022 Apr;17(4):558-567. doi: 10.1016/j.jtho.2021.11.025. Epub 2021 Dec 24. J Thorac Oncol. 2022. PMID: 34958928 Free article. Clinical Trial.
The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
Brown TJ, Yablonovitch A, Till JE, Yen J, Kiedrowski LA, Hood R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Carpenter EL, Nathanson K, Domchek SM, Reiss KA. Brown TJ, et al. Among authors: yablonovitch a. Clin Cancer Res. 2023 Dec 15;29(24):5207-5216. doi: 10.1158/1078-0432.CCR-23-1467. Clin Cancer Res. 2023. PMID: 37486343
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Harvey-Jones E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, Alaguthurai T, Yablonovitch A, Yen J, Xiao H, Brough R, Frankum J, Song F, Yeung J, Savy T, Gulati A, Alexander J, Kemp H, Starling C, Konde A, Marlow R, Cheang M, Proszek P, Hubank M, Cai M, Trendell J, Lu R, Liccardo R, Ravindran N, Llop-Guevara A, Rodriguez O, Balmana J, Lukashchuk N, Dorschner M, Drusbosky L, Roxanis I, Serra V, Haider S, Pettitt SJ, Lord CJ, Tutt ANJ. Harvey-Jones E, et al. Among authors: yablonovitch a. Ann Oncol. 2024 Apr;35(4):364-380. doi: 10.1016/j.annonc.2024.01.003. Epub 2024 Jan 19. Ann Oncol. 2024. PMID: 38244928 Free article.
The evolution and adaptation of A-to-I RNA editing.
Yablonovitch AL, Deng P, Jacobson D, Li JB. Yablonovitch AL, et al. PLoS Genet. 2017 Nov 28;13(11):e1007064. doi: 10.1371/journal.pgen.1007064. eCollection 2017 Nov. PLoS Genet. 2017. PMID: 29182635 Free PMC article. Review.
Fluorescent indicators for simultaneous reporting of all four cell cycle phases.
Bajar BT, Lam AJ, Badiee RK, Oh YH, Chu J, Zhou XX, Kim N, Kim BB, Chung M, Yablonovitch AL, Cruz BF, Kulalert K, Tao JJ, Meyer T, Su XD, Lin MZ. Bajar BT, et al. Among authors: yablonovitch al. Nat Methods. 2016 Dec;13(12):993-996. doi: 10.1038/nmeth.4045. Epub 2016 Oct 31. Nat Methods. 2016. PMID: 27798610 Free PMC article.
The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans.
Zheng M, Zhang H, Dill DL, Clark JD, Tu S, Yablonovitch AL, Tan MH, Zhang R, Rujescu D, Wu M, Tessarollo L, Vieira W, Gottesman MM, Deng S, Eberlin LS, Zare RN, Billard JM, Gillet JP, Li JB, Peltz G. Zheng M, et al. Among authors: yablonovitch al. PLoS Med. 2015 Feb 3;12(2):e1001782. doi: 10.1371/journal.pmed.1001782. eCollection 2015 Feb. PLoS Med. 2015. PMID: 25647612 Free PMC article.